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 Noninvasive Determination of 2-[
18F]-Fluoroisonicotinic Acid
Hydrazide Pharmacokinetics by Positron Emission Tomography in
Mycobacterium tuberculosis-Infected Mice
E. A. Weinstein,
a,b,c L. Liu,
d A. A. Ordonez,
a,b,e H. Wang,
d J. M. Hooker,
f P. J. Tonge,
d and S. K. Jain
a,b,e
Center for Infection and Inﬂammation Imaging,
a Center for Tuberculosis Research,
b Department of Medicine,
c and Department of Pediatrics,
e Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA; Institute for Chemical Biology & Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York,
USA
d; and Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
f
Tuberculosis(TB)isaglobalpandemicrequiringsustainedtherapytofacilitatecuringandtopreventtheemergenceofdrug
resistance. There are few adequate tools to evaluate drug dynamics within infected tissues in vivo. In this report, we evaluated a
ﬂuorinatedanalogofisoniazid(INH),2-[
18F]ﬂuoroisonicotinicacidhydrazide(2-[
18F]-INH),asaprobeforimaging Mycobacte-
rium tuberculosis-infected mice by dynamic positron emission tomography (PET). We developed a tail vein catheter system to
safely deliver drugs to M. tuberculosis aerosol-infected mice inside sealed biocontainment devices. Imaging was rapid and non-
invasive,anditcouldsimultaneouslyvisualizemultipletissues.DynamicPETimagingdemonstratedthat2-[
18F]-INHwasex-
tensivelydistributedandrapidlyaccumulatedatthesitesofinfection,includingnecroticpulmonaryTBlesions.Comparedto
uninfected animals, M. tuberculosis-infected mice had a signiﬁcantly higher PET signal within the lungs (P < 0.05) despite simi-
larPETactivityintheliver(P>0.85),suggestingthat2-[
18F]-INHaccumulatedatthesiteofthepulmonaryinfection.Further-
more,ourdataindicatedthatsimilartoINH,2-[
18F]-INHrequiredspeciﬁcactivationandaccumulatedwithinthebacterium.
Pathogen-speciﬁcmetabolismmakespositron-emittingINHanalogsattractivecandidatesfordevelopmentintoimagingprobes
with the potential to both detect bacteria and yield pharmacokinetic data in situ. Since PET imaging is currently used clinically,
thisapproachcouldbetranslatedfrompreclinicalstudiestouseinhumans.
T
heimportanceofsustained,adequateantimicrobialtherapyis
highlighted by Mycobacterium tuberculosis, which is causing a
surging global epidemic with an estimated 8.8 million new pa-
tients with active disease and 1.5 million deaths annually (41).
Manyofthe2.2billionpeoplelatentlyinfectedwithM.tuberculo-
sisdevelopreactivationdisease,sometimesdecadesaftertheinitial
infection (19). Coinfection with human immunodeﬁciency virus
(HIV)increasestheriskofrelapsefromalifetimeriskof5to10%
to approximately 10% per year (10).
Tuberculosis(TB)istypicallytreatedwith6monthsofcombi-
nationtherapyusingisoniazid(INH)asaprimaryagentduetoits
remarkable sterilizing activity against actively dividing bacilli (9,
10). The treatment regimen was developed using serum pharma-
cokinetic (PK) values and historic measures of efﬁcacy (5, 16).
Nevertheless, a growing number of studies support the impor-
tance of monitoring drug concentration in infected tissues (17,
26),andcurrentFoodandDrugAdministration(FDA)guidelines
requiretissuedrugdistributionstudiesatinfectedanduninfected
sites(26).Seriousconsequencesofinadequatedrugconcentration
in target tissues include treatment failure and selection pressure
for antibiotic-resistant organisms (31). Conversely, in severely ill
patients, normal physiology may be compromised, thus elevating
the risk of renal and hepatic toxicity (24).
INHisaprodrugwithcomplexbacterialmetabolism.Consen-
sus holds that it is ﬁrst oxidized by the mycobacterial catalase-
peroxidase enzyme KatG and then conjugates with NAD (39, 42)
to form an INH-NAD adduct that inhibits the enoyl-acyl carrier
protein (enoyl-ACP) reductase InhA, among other targets (3, 27,
34, 39, 42). INH is hypothesized to accumulate within the myco-
bacterium as trapped metabolites, including the INH-NAD ad-
duct,whichdissociatesslowlyfromInhA(22,33).Toevaluatethis
hypothesis and explore the potential of INH as a reporter of bac-
terial localization in vivo, a method is needed that can report on
drug concentration at the site of infection. New techniques, such
as matrix-assisted laser desorption ionization (MALDI) mass
spectrometry, have the power to detect drugs and their metabo-
liteswithinagranuloma(32)butareinvasiveandrelyonaccurate
resectionoftissue.Positronemissiontomography(PET)isanon-
invasive alternative to determine the characteristics of drug ab-
sorption, distribution, and elimination in both clinical and pre-
clinicalsettings(8,12,20).Thepathogen-speciﬁcmetabolismand
accumulation of INH makes it an attractive imaging probe with
thepotentialtobothdetectbacteriaandyieldPKdatainsitu(15).
We recently reported the bioimaging of [
11C]-INH and two other
carbon-11-labeled TB therapeutics in healthy baboons (20). We
have now extended this work to the evaluation of a ﬂuorine-18
analog of INH, which also has the advantage of translation to
clinical settings (25). Furthermore, we have progressed from
healthy control animals to imaging animals with active M. tuber-
culosis infections. To accomplish this safely, we developed and
utilized a novel on-table injection system to noninvasively deter-
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 mineamultitissuehostpharmacokineticproﬁleof2-[
18F]-INHin
M. tuberculosis-infected mice.
MATERIALS AND METHODS
The chemicals used in the study all were purchased from commercial
vendors and were used without further puriﬁcation except where stated.
18F was purchased from PETNET Solutions Inc. (Philadelphia, PA) on
ion-exchange resin. Chemical and radiochemical purities were deter-
mined by thin-layer chromatography (TLC) and an analytical high-per-
formanceliquidchromatography(HPLC)systemequippedwithbothUV
and radioactivity detectors. The purities of the intermediate and ﬁnal
products were 95%.
Synthesis of 2-F-INH and 2-[
18F]-INH. The syntheses of 2-ﬂuoro-
isonicotinic acid hydrazide (2-F-INH) and 2-[
18F]ﬂuoro-isonicotinic
acid hydrazide (2-[
18F]-INH) were performed from 2-ﬂuoropyridine-4-
carboxylic acid as described previously (2, 35) (see Fig. S1 in the supple-
mental material for details). Radiochemical purity was determined by
reverse-phase analytical high-performance liquid chromatography
(HPLC) (PFP; 250 by 4.6, 5-m column; Phenomenex) using a mobile
phaseof5%MeCN–95%H2OandconﬁrmedbyTLC(10%MeOH–90%
CH2Cl2) cospotting of the labeled product with a standard.
Inactivation of InhA by INH or 2-F-INH. The M. tuberculosis enoyl-
ACPreductase(InhA)wasexpressedandpuriﬁedaspreviouslydescribed
(23), and catalase peroxidase (KatG) was provided as a gift from Richard
Magliozzo (Department of Chemistry, Brooklyn College, NY). Trans-2-
dodecenoyl-coenzyme A (DD-CoA) was synthesized from trans-dode-
cenoic acid as previously described (29). InhA (0.5 M) was incubated
with 0.5 M KatG, 50 M NAD
,5 0M INH (or F-INH), and 2 mM
EDTA in a total volume of 1.0 ml at 25°C in buffer [30 mM piperazine-
N,N=-bis(2-ethanesulfonic acid), 150 mM NaCl, pH 6.8]. Aliquots were
taken at 5, 10, 20, 30, 40, 50, 60, 90, and 120 min, and then DD-CoA (20
M) and NADH (250 M) were added. InhA activity was measured by
following the oxidation of NADH to NAD
 at 340 nm in a Cary 100 Bio
spectrophotometer (Varian). InhA activity was expressed as a percentage
of the value measured at time zero (43). Three independent replicates
were used for each group.
M. tuberculosis strains and in vitro uptake assays. Frozen stocks of
wild-type M. tuberculosis H37Rv as well as previously validated katG
W149R, katG M1A, and inhA T(8) INH-resistant strains in the M. tu-
berculosisH37Rvbackground(1)weregrowntomid-logphaseinMiddle-
brook 7H9 broth supplemented with 10% oleic acid-albumin-dextrose-
catalase (Difco, Detroit, MI) and 0.05% Tween 80 (Sigma). MICs were
determinedforeachstrainwithINHand2-F-INHbythebrothmacrodi-
lution method (National Committee for Clinical Laboratory Standard
M07-A8). 2-[
18F]-INH uptake assays were performed by incubating bac-
terial cultures with 0.148 MBq per ml of 2-[
18F]-INH at 37°C with rapid
agitationfor8h.Heat-killed(90°Cfor20min)controlsforeachbacterial
strain were similarly incubated with 2-[
18F]-INH. Bacteria were pelleted
by centrifugation and washed twice with phosphate-buffered saline
(PBS). All live bacterial cultures were heat inactivated prior to measure-
ments. The activity for each pellet was measured using an automated
gammacounter(1282CompugammaCSUniversalgammacounter;LKB
Wallac). Background counts were subtracted from sample counts. Five
independent replicates were used for each sample.
Murine M. tuberculosis model (in vivo aerosol infection). Five- to
6-week-old female BALB/c (Charles River) or C3HeB/FeJ (Jackson Labo-
ratory) mice were aerosol infected with log-phase broth cultures of M.
tuberculosis H37Rv using the Middlebrook inhalation exposure system
(Glas-Col). Mice were sacriﬁced the day after infection to determine the
number of bacilli implanted in the lungs and also at the time of imaging.
The entire lungs were homogenized in phosphate-buffered saline and
plated onto Middlebrook 7H11 selective plates (Becton, Dickinson). At
least 3 mice were used for each time point. All plates were incubated at
37°C for 4 weeks before the CFU were determined. A separate group of
identically infected mice were used for imaging studies.
On-table injection system. A 30-gauge needle (BD Bioscience), at-
tached to polyethylene-10 tubing (Braintree Scientiﬁc), was inserted into
thelateraltailveinofanesthetizedM.tuberculosis-infectedmiceasacath-
eterforon-tabletracerdelivery(seeFig.S2inthesupplementalmaterial).
Theliveanimalswerethenplacedinsidesealedbiocontainmentdevicesas
described before (7, 8), with the polyethylene-10 tubing extending
through one of the ports of the biocontainment device. The device was
seal tested, and a 1-ml insulin syringe was attached to the catheter hub to
deliver radiotracer at the beginning of imaging.
[
18F]FDG-PETandCTimaging.Micewerefastedfor12hbeforeeach
imaging time point. Water was provided ad libitum. On the day of imag-
ing,eachmousewasweighed,anesthetized,andtheninjectedwith(nom-
inally)7.4MBqof[
18F]-ﬂuorodeoxyglucose([
18F]-FDG)viathetailvein
and imaged 45 min postinjection using a Mosaic HP (Philips) small-
animalPETimagerusingasingle-frame,15-minacquisition.Acomputed
tomography (CT) scan was also performed at the same time using the
NanoSPECT/CT (Bioscan) in vivo animal imager. PET images were re-
constructed and coregistered with CT images. Three mice were used for
eachgroup.Amiraversion5.4.2(Amira)wasusedtovisualizetheimages.
2-[
18F]-INH-PET/CT imaging. One week later, the same mice previ-
ously imaged by [
18F]-FDG were weighed, injected with (nominally) 7.4
MBq of 2-[
18F]-INH via the tail vein, and imaged. Since
18F has a radio-
active half-life of 109 min, it is completely decayed and does not interfere
withthe2-[
18F]-INHimaging1weeklater.C3HeB/FeJmicewereimaged
20 min postinjection using the Mosaic HP (Philips) small-animal PET
imagerswithadynamic(listmode)acquisitionfor120min.BALB/cmice
were imaged immediately after tracer injection by utilizing the on-table
injectionsystem.List-modedatawereframedasfollows:5timesfor2min
each, and then 10 times for 5 min each. Infected and uninfected controls
werescannedtwoatatimeasmatchedpairs,anddatawereobtainedfrom
3 matched pairs (3 infected and 3 uninfected animals). CT scans were
performed subsequent to PET imaging using the NanoSPECT/CT (Bio-
scan) in vivo animal imager. PET data were reconstructed and coregis-
tered with CT images. Three mice were used for each group.
For semiquantitative analysis, 1 to 2 spherical (3-mm-diameter) re-
gions of interest (ROI) were drawn manually using Amide version 0.9.1
(amide.sourceforge.net) in the lung, liver, and brain ﬁelds using CT as a
guide. The standard uptake values (SUV) were computed by normalizing
the ROI activity for each mouse to the injected dose and animal weight.
For each group, the mean lung uptake of radioactivity at each time point
wascalculatedbyaveragingthenormalizedlungSUVofalloftheROIsin
that group. Amira was used to visualize the images.
All protocols were approved by the Johns Hopkins Biosafety, Radia-
tion Safety, and Animal Care and Use Committees.
Statistical analysis. Statistical comparison between groups was per-
formed using one-tail-distribution, two-sample, unequal-variance t tests
inExcel2007(Microsoft).Dataarepresentedonalinearscaleasmeans
standard errors for mean PET activities.
RESULTS
2-F-INH accumulates in M. tuberculosis. Respective MICs for
2-F-INH and INH were 8 and 0.025 g/ml for the wild-type M.
tuberculosis, 32 and 2 g/ml for the katG promoter mutant
(M1A), 32 and 1 g/ml for the katG point mutant (W149R),
and 32 and 0.1 g/ml for the inhA promoter mutant [T(8)].
Time-dependent inactivation of InhA by INH and 2-F-INH as
measuredbymonitoringtheoxidationofNADHinvitroisshown
in Fig. 1A. Inactivation of InhA followed ﬁrst-order kinetics for
the ﬁrst 60 min with a rate constant of 0.0299 and 0.0104 min
1
for INH and 2-F-INH, respectively. Complete inhibition of InhA
wasachievedwithin90minwithINH,whereas2-F-INHrequired
over 120 min. In the control groups (without KatG), InhA was
only minimally inhibited by either INH or 2-F-INH, conﬁrming
that both INH and 2-F-INH required KatG activation prior to
Imaging Fluoroisoniazid Pharmacokinetics In Vivo
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 InhA inhibition. Finally, we tested the intracellular accumulation
of 2-[
18F]-INH in wild-type M. tuberculosis and INH-resistant
strains (Fig. 1B). Following an 8-h incubation, 2-[
18F]-INH read-
ily accumulated within wild-type M. tuberculosis. Only the most
INH-resistant strain, katG M1A, demonstrated signiﬁcantly re-
duced intracellular accumulation of 2-[
18F]-INH. No accumula-
tion of 2-[
18F]-INH was noted in any of the heat-killed strains
(data not shown). Taken together, these data indicate that al-
though the 2-ﬂuoro group signiﬁcantly reduces the antibacterial
activity of INH and decreases the ability of INH to inhibit InhA,
2-F-INH follows a pattern of metabolism and bacterial uptake
similar to that of INH.
PET imaging of 2-[
18F]-INH in M. tuberculosis-infected
mice. We hypothesized that the metabolism of INH by M. tuber-
culosis KatG results in selective intracellular trapping of INH and
therefore generates a speciﬁc PET signal at the site of TB disease.
2-[
18F]-INH was synthesized and puriﬁed by a modiﬁed method
of Amartey et al. (2) with resultant speciﬁc activity of 7.4 to 11.1
MBq/mol at the time of delivery to the animal.
Aerosol-infectedBALB/cmicewereimaged8weekspostinfec-
tion, at which point there was diffuse pulmonary disease and
log10(6.40.3)CFUinthelungs.Therewasnosigniﬁcantdiffer-
ence in weight between the infected and uninfected animals.
Coregistered [
18F]FDG-PET and CT images of a representative
matchedpairareshowninFig.2A.Asexpected,diffuse[
18F]FDG-
PET activity was noted in the lung ﬁelds in infected animals but
not in uninfected animals. Background uptake was noted in the
heart, kidneys, and bladder of both the uninfected and infected
animals. Coregistered 2-[
18F]-INH-PET/CT images from the
sameanimalsareshowninFig.2B.DiffusePETactivitywasagain
noted in the lung ﬁelds in the infected animal but not the unin-
fected mouse. Background PET signal in the heart, liver, kidneys,
and bladder was noted in both infected and uninfected animals.
Similar experiments were performed in C3HeB/FeJ mice for
theirintrinsicabilitytoformlocalizedandwell-deﬁnedTBlesions
with central necrosis and hypoxia (13, 28). Mice were imaged 17
weeksafteralow-doseaerosolinfection,atwhichpointtherewere
well-deﬁned pulmonary lesions and log10(6.7  0.3) CFU in the
lungs.Discretefociof2-[
18F]-INH-PETactivitycolocalizingwith
the TB lesions (as seen on CT) were noted in the lung ﬁelds of the
infectedmousebutnotintheuninfectedanimal(Fig.3),suggest-
ingthat2-[
18F]-INHpenetratedandconcentratedatthesiteofTB
lesions. As expected, and similar to that for BALB/c mice, uptake
intheheart,liver,kidneys,andbladderwasnotedinbothinfected
and uninfected animals.
Organ compartment pharmacokinetics of 2-[
18F]-INH.
Given the qualitative differences in 2-[
18F]-INH-PET signal be-
tween M. tuberculosis-infected and uninfected mice, we per-
formed additional quantitative analyses. Following simultaneous
2-[
18F]-INH injections into paired infected and uninfected
BALB/cmice,weperformeddynamicPETacquisitionsovertime.
As shown in Fig. 4A, there was signiﬁcantly more 2-[
18F]-INH-
PET activity in the lung ﬁelds of infected mice than in uninfected
controls from 40 min postinjection to the end of the recording at
60 min (P  0.05). A signal-to-background ratio of 1.67  0.04
was achieved from 40 to 60 min after tracer injection. Similarly,
uptake of 2-[
18F]-INH was also evaluated in the brain. Probe up-
take peaked 15 min postinjection and then slowly diffused away
(Fig. 4B). While the signal was greater in infected mice, it was not
statisticallysigniﬁcant(P0.50).Asexpected,theliverintensities
were not signiﬁcantly different (P  0.85) between the infected
and uninfected animals (Fig. 4C) but they demonstrated high ac-
tivity, as this is the site of INH metabolism. To extrapolate these
dataintoatherapeuticcontext,anINHdoseof6.25mg/kgofbody
weight in BALB/c mice produces a maximum concentration of
drug in serum (Cmax)o f4g/ml at 15 min (1). Using the heart as
a proxy for the whole-blood concentration of 2-[
18F]-INH, the
Cmax in infected lung is calculated to be 3.5 g/ml, and it is 3.3
g/ml in uninfected controls. The differential uptake ratios of
heart,lung,brain,liver,andkidneythatcorrespondtotheCmax(at
the 15-min time point) are presented in Table S1 in the supple-
mental material.
DISCUSSION
INHhasbeenthemainstayofTBtreatmentsinceitsintroduction
in 1952 (6, 33). While the absorption from the gastrointestinal
FIG1 2-F-INHinhibitsInhAandaccumulatesinM.tuberculosis.(A)Thetime-dependentinactivationofInhAbyINHand2-ﬂuoroisonicotinicacidhydrazide
(2-F-INH)wasmeasuredbymonitoringtheoxidationofNADHinvitro.Threeindependentreplicateswereusedforeachgroup.TheInhAactivityisexpressed
as a percentage of the activity measured at time zero. Complete inhibition of InhA was achieved within 90 min with INH, whereas 2-F-INH required about 120
min. In the control groups (omission of KatG), InhA is only minimally inhibited for both INH and 2-F-INH. (B) Intracellular accumulation of 2-[
18F]-INH in
INH-resistant strains following an 8-h incubation is shown as a percentage of uptake compared to that of wild-type M. tuberculosis. Five independent replicates
were used for each group. 2-[
18F]-INH readily accumulates within wild-type M. tuberculosis, and only the most INH-resistant strain (katG M1A) demonstrates
signiﬁcantly reduced intracellular accumulation. Taken together, these data indicate that although the addition of ﬂuorine at the second position signiﬁcantly
decreasesactivityagainstInhA,2-F-INHfollowsapatternofmetabolismandbacterialuptakesimilartothatofINH.Errorbarsrepresentthestandarderrorsof
the means.
Weinstein et al.
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 tract is rapid and biodistribution nearly approaches that of water
(20, 40), the elimination of drug depends on age and genetic fac-
tors, following a trimodal distribution in the general population
(30, 36). The pharmacokinetic variability of INH metabolism is
associated with treatment failure as well as acquired drug resis-
tance (31). Indeed, drug levels were found to be subtherapeutic
among patients with a slow response to TB therapy, suggesting
that individualized dosing is more effective than standard dosing
(14). Like most antimicrobial agents, INH requires transport to
thesiteofinfectionandinteractionwiththepathogen.Asaresult,
determining the drug concentration at the site of action is a more
accurate approach to determining pharmacodynamic relation-
shipsthanplasmadrugconcentration(4).Traditionalpharmaco-
kinetic methods involve the sacriﬁce and dissection of animals,
which in itself alters tissue physiology. One solution to this di-
lemma has been the use of clinical microdialysis for continuous
monitoring of drug bioavailability (37), but the technique re-
quirespreciseanatomicknowledgeofthelesionlocationforprobe
insertion. TB produces diverse lesions that are often difﬁcult to
localize (11). In the current study, we therefore utilized PET im-
FIG 2 PET/CT imaging of M. tuberculosis-infected mice with diffuse pulmonary disease. Infected and uninfected BALB/c pairs were imaged after injection of
2-[
18F]-FDG(A)or2-[
18F]-INH(B).Whole-animalsagittalandtransversesectionsaredisplayedascombinedPET/CTimageswithheart(H),liver(L),kidneys
(K),spleen(S),andbladder(B)marked.[
18F]FDG-PETactivityisnotedinthelungﬁeldsininfectedanimalsbutnotuninfectedanimals(A).Backgrounduptake
is noted in the heart, kidneys, and bladder of both the uninfected and infected animals. Similarly, diffuse 2-[
18F]-INH-PET activity is noted in the lung ﬁelds of
the infected animal but not the uninfected mouse (B). Background PET signal in the heart, liver, kidneys, and bladder is noted in both infected and uninfected
animals.
Imaging Fluoroisoniazid Pharmacokinetics In Vivo
December 2012 Volume 56 Number 12 aac.asm.org 6287
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 aging, which can evaluate disease processes in live animals, deep
withinthebody,noninvasivelyandrelativelyrapidly.Anon-table
injection and biocontainment system, developed in house, al-
lowedustodeterminethereal-timepharmacokineticproﬁleofan
18F analog of INH in M. tuberculosis-infected mice. The approach
was rapid and noninvasive and visualized the entire animal.
Our data support that similar to INH, 2-F-INH is activated by
KatG and accumulates intracellularly in bacteria, but it has re-
duced activity against InhA. The weaker inhibition of InhA rela-
tive to INH may explain the decreased antibacterial activity of
2-F-INH against M. tuberculosis. Nevertheless, pathogen-speciﬁc
enzymatic activation and presumed intracellular trapping make
2-F-INH an interesting candidate as an imaging probe for M. tu-
berculosis and for studying INH pharmacokinetics. By imaging
infected and uninfected animals simultaneously, we not only de-
termined organ-speciﬁc drug dynamics in challenging compart-
ments like the central nervous system but also noted accumula-
tion of 2-[
18F]-INH in the lungs. Diffuse 2-[
18F]-INH-PET
activity was noted in the lungs of infected BALB/c mice with a
signal-to-backgroundratioof1.67at60minaftertracerinjection.
FIG3 PET/CTimagingofM.tuberculosis-infectedmicewithdiscreteTBlesions,centralnecrosis,andhypoxia.Uninfected(A)andinfected(B)C3HeB/FeJpairs
were imaged after injection of 2-[
18F]-FDG (A) or 2-[
18F]-INH (B). Whole-animal sagittal and transverse sections are displayed as combined PET/CT images
withheart(H),liver(L),kidneys(K),andbladder(B)marked.Discretefociof2-[
18F]-INH-PETactivitycolocalizingwiththeTBlesions(asseenonCT)isnoted
inthelungﬁeldsoftheinfected(B)butnottheuninfectedmouse(A),suggestingthat2-[
18F]-INHpenetratesandconcentratesatthesiteofTBlesions.Uptake
in the heart, liver, kidneys, and bladder is noted in both infected and uninfected animals.
Weinstein et al.
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 This is greater than the 1.32 ratio at 15 min (see Table S1 in the
supplemental material) in the lungs, suggesting that these ratios
increase with time, presumably due to the selective retention of
2-[
18F]-INH in infected tissues and the clearance of the back-
ground signal from uninfected tissues. Moreover, discrete foci of
PET activity corresponding to the bacterium-rich TB lesions (8)
werenotedinthelungsofinfectedC3HeB/FeJmice.Whileanon-
speciﬁc blood-pooling effect could be contributing in part to the
higher PET activity noted in the lungs of infected animals, the
similar levels of 2-[
18F]-INH PET activity noted in the livers of
infectedversusuninfectedmiceargueagainstthisasthedominant
phenomena. In our analysis of the brain, we found that 2-[
18F]-
INH activity peaked 15 min after administration, consistent with
the known rapid transit of INH across the blood-brain barrier
(20).
We have previously utilized pulmonary [
18F]FDG-PET imag-
ing to monitor the response to TB treatments (8). However,
[
18F]FDG is a nonspeciﬁc marker of metabolic activity that relies
upon a host inﬂammatory response. The various M. tuberculosis
strainsproducedifferingamountsofimmuneresponse,withBei-
jing/W producing signiﬁcantly more inﬂammation than Canetti
intheBALB/cmousemodelofpulmonaryinfection(21).2-[
18F]-
INH therefore would be predicted to be more sensitive than
[
18F]FDG-PET for diagnosis of the less virulent strains of TB. In
addition, [
18F]FDG-PET cannot discriminate sterile inﬂamma-
tionfrominfection(38).Bytargetingpathogenmetabolismrather
than the inﬂammatory response of the host,
18F analogs of INH
could be more speciﬁc agents for detecting and monitoring TB
treatments.SinceactivatedINHbindswithasigniﬁcantresidence
time to InhA and is presumably trapped within bacteria, increas-
ing the interval between tracer administration and imaging could
further increase the signal-to-noise ratio by allowing the washout
ofthebackgroundPETsignal.Sincethehalf-lifeof
18Fisonly109
min,useofalonger-livedPETisotope,suchas
124I(half-lifeof4.2
days), could be used to achieve this goal. Finally, the capacity to
differentiate disease by INH-resistant strains would also be a use-
ful corollary of 2-[
18F]-INH imaging. Unfortunately this was not
tested in the current study, since KatG is a signiﬁcant virulence
factor required for M. tuberculosis growth in vivo (18), and there-
fore it would be difﬁcult to generate comparable disease or bacte-
rial burden with the INH-resistant strains in our models. Addi-
tionallimitationstotheprobeincluderelativelyhighbackground
signal in the liver, heart, and bladder. In the case of disseminated
infection, a bacterial signal from these tissues would be obscured
with the current shorter half-life of 2-[
18F]-INH.
Insummary,wevalidatedaﬂuorinatedanalogofINH,2-[
18F]-
INH, as an imaging probe for determining drug PK in M. tuber-
culosis-infectedmice.Thisapproachisrapidandnoninvasive,and
it can simultaneously visualize multiple compartments. The
pathogen-speciﬁcmetabolismofINHmakesitanattractivetarget
for development as an imaging probe. The use of longer-lived
positron-emitting isotopes may provide greater signal speciﬁcity
and allow for development as a TB biomarker. Finally, since PET
imaging is extensively used in humans, this technology is applica-
bleforbothpreclinicalandclinicalstudieswithsigniﬁcantpoten-
tial for translation to other anti-infectives.
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FIG 4 Organ compartment pharmacokinetics of 2-[
18F]-INH. Following si-
multaneous 2-[
18F]-INH injections into paired infected and uninfected
BALB/c mice, we performed dynamic PET acquisitions over time. There is
signiﬁcantly more 2-[
18F]-INH-PET activity in the lung ﬁelds (A) of infected
mice than in uninfected controls from 40 min postinjection to the end of the
recordingat60min(P0.05).Uptakeof2-[
18F]-INHwasevaluatedsimilarly
in the brain (B). Probe uptake peaks at 15 min postinjection and then slowly
diffuses away. While the signal is greater in infected mice, it is not statistically
signiﬁcant (P  0.50). As expected, the liver intensities are not signiﬁcantly
different (P  0.85) between the infected and uninfected animals (C) but
demonstrate high activity, as this is the site of INH metabolism.
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 Noninvasive Determination of 2-[
18F]-Fluoroisonicotinic Acid
Hydrazide Pharmacokinetics by Positron Emission Tomography in
Mycobacterium tuberculosis-Infected Mice
E. A. Weinstein, L. Liu, A. A. Ordonez, H. Wang, J. M. Hooker, P. J. Tonge, S. K. Jain
Center for Infection and Inﬂammation Imaging, Center for Tuberculosis Research, Department of Medicine, and Department of Pediatrics, Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA; Institute for Chemical Biology & Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York,
USA; Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
Volume 56, no. 12, p. 6284–6290, 2012. Page 6288: Figure 3 legend, lines 1 and 2, “Uninfected (A) and infected (B) C3HeB/FeJ pairs
were imaged after injection of 2-[
18F]-FDG (A) or 2-[
18F]-INH (B)” should read “Uninfected (A) and infected (B) C3HeB/FeJ pairs
were imaged after injection of 2-[
18F]-INH.”
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